Bradmer announces Dr. Phil Gold to join Board of Directors



    TSX: BMR

    TORONTO, Aug. 15 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced that Phil Gold, C.C., O.Q., M.D., Ph.D.,
has agreed to join the Company's Board of Directors effective immediately.
Dr. Gold is a pioneer in the study of oncology and physiology with over 40
years of experience in clinical and academic settings. His early research led
to the discovery and definition of the Carcinoembryonic Antigen (CEA), the
blood test most frequently used in the diagnosis and management of patients
with cancer.
    "Dr. Gold's extensive experience in the study and management of cancer
will be of great benefit to our Board of Directors and the senior management
team at Bradmer," said Mark C. Rogers, M.D., Executive Chairman of Bradmer.
"As one of the most prominent clinical investigators in Montreal, Dr. Gold has
demonstrated a commitment, over the course of his career, to help patients
through direct patient care as well as working with the pharmaceutical
industry in developing innovative new therapies. The addition of Dr. Gold is
an example of Bradmer's ability, based on our novel Neuradiab therapy, to
attract thought leaders in the oncology space."
    Dr. Gold is currently the Executive Director of the Clinical Research
Centre of the McGill University Health Centre. He has also served as Chairman
of the Department of Medicine at McGill and Physician-in-Chief at the Montreal
General Hospital. Dr. Gold has been elected to numerous professional
organizations including the American Society for Clinical Investigation, the
Association of American Physicians, and Mastership in the American College of
Physicians. He has been the recipient of a number of prestigious awards
including his appointment as a Companion of the Order of Canada and the
Robert Taylor Gold Medal from the National Cancer Institute of Canada.
Dr. Gold is a graduate of McGill University where he completed his B.Sc. and
M.Sc. in physiology and where he later completed his MDCM and Ph.D. In 2006,
the Phil Gold Chair in Medicine was inaugurated at McGill University. Dr. Gold
will be replacing Mr. Doug Janzen, President and Chief Business Officer of
Cardiome Pharma Corp. (NASDAQ:   CRME, TSX: COM) on the Board of Bradmer.

    About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

    Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a pivotal multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Agency.

    Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
laws.

    Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00023367E




For further information:

For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business and Financial Officer, Phone: (416) 361-6058 (Ext.
804), E-mail: bbrohman@bradmerpharma.com, Internet: www.bradmerpharma.com;
Investor Relations, Ross Marshall, The Equicom Group Inc., Phone: (416)
815-0700 (Ext. 238), Fax: (416) 815-0080, E-mail: rmarshall@equicomgroup.com

Organization Profile

BRADMER PHARMACEUTICALS INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890